Answers are grounded in this paper and cite their sources.
Case report reveals fatal isolated endobronchial aspergillosis in an immunocompromised patient, highlighting the aggressive nature of airway fungal infection without parenchymal lung disease.
Endobronchial aspergillosis (EBA) is an uncommon manifestation of Aspergillus airway disease characterized by fungal involvement of the tracheobronchial lumen. It may present with non‐specific respiratory symptoms, including dyspnea, cough and hemoptysis, and can mimic endoluminal airway tumours. Predisposing factors include immunosuppressive conditions such as corticosteroid therapy, malignancy, chemotherapy and neutropenia. Definitive diagnosis relies on bronchoscopic evaluation with histopathological confirmation. Due to its rarity, evidence regarding optimal management remains limited. This case emphasizes that isolated airway Aspergillus infection may occur without parenchymal lung involvement and may be associated with a rapidly fatal clinical course despite prompt antifungal therapy.
No takes yet. Share an insight, caveat, or question.
Sadeghi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: